Guest writer Matthew Busch says that, despite the setbacks and surgeries he's endured, he's now thriving in life with Duchenne MD.

The FDA's verdict on PTC's Translarna could spell the end for the drug's decades-long and tumultuous US DMD development ...

My twin sister spent years moving through consultations without a clear explanation for her symptoms. At one point, aged 31, she was told it was “wear and tear”. At another, she was advised she might ...

A 12-year-old boy, identified as AA, is fighting a battle far beyond his years. He suffers from Duchenne muscular dystrophy, a disease that silently ...

Arriana Washington was arrested after the emaciated dog was discovered off Ingwood Avenue in New Smyrna Beach.

Azeem Ahmed launched Equal Clothing in 2023 to show those with severe disabilities that they can achieve their dreams - even if other people don't believe they can.

With the writing apparently on the wall, PTC Therapeutics has called off its latest bid for FDA approval of its Duchenne muscular dystrophy (DMD) drug Translarna.  | Late Thursday, PTC revealed that ...

PTC Therapeutics, Inc. (PTCT) stock closed lower following the withdrawal of its New Drug Application for Translarna by the FDA.

Regenxbio advances RGX-314 and RGX-202 pipelines for AMD and Duchenne while navigating recent FDA program setbacks. Read why RGNX stock is downgraded to buy.

After two decades of work with Translarna (ataluren) for nonsense mutation Duchenne muscular dystrophy, PTC Therapeutics Inc. withdrew its bid for approval of the compound upon hearing from the U.S.

PTC Therapeutics withdrew a New Drug Application for Translarna, a muscular dystrophy treatment, after the Food and Drug Administration indicated it would likely not grant approval.

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has withdrawn the New Drug Application (NDA) resubmission for ...